Yilmaz Seyhan, Kiziltan Feryaz, Zengin Sabur, Kalender Mehmet, Cam Isa
Associate Professor, Department of Cardiovascular Surgery, Corlu Province Hospital, Tekirdag, Turkey.
Department of Cardiovascular Surgery, Umraniye Education and Research Hospital, Istanbul, Turkey.
ARYA Atheroscler. 2022 Jan;18(1):1-6. doi: 10.48305/arya.v18i1.2374.
Cyanoacrylate (CA) has been used as an embolizing agent in the treatment of greater saphenous vein (GSV) insufficiency in recent years and the results regarding the use of this method have started to be published. To the best of our knowledge, the publications in literature do not mention about a significant negative effect of endovenous CA (EVCA) embolization. We aimed to evaluate the effects and undesirable events of this relatively new treatment method and compare them with literature, using the follow-up data of our patients.
Patients who had GSV insufficiency for at least 3 months and were treated with EVCA embolization because of this disease were included in the study. Patients were excluded if they had deep vein thrombosis (DVT), excessive tortuous GSV, and peripheral neuropathy. Hospital archive records were reviewed and undesirable events like DVT, thrombophlebitis, and pain related to this treatment procedure were recorded.
EVCA embolization procedure was performed in a total of 54 patients with an average age of 49.36 ± 13.06 years for the purpose of treating GSV insufficiency. One patient was observed to develop n-butyl CA (NBCA) extension of approximately 5 mm from saphenofemoral junction (SFJ) to the main femoral vein and painful thrombophlebitic reaction was observed in 6 extremities at the first control examination.
In our opinion, while EVCA embolization is a treatment option with similar success rates to endovenous thermal ablation (EVTA), it should be kept in mind that there may be a possibility of developing thrombophlebitis and NBCA extension or thrombus extension to the deep veins.
近年来，氰基丙烯酸酯（CA）已被用作治疗大隐静脉（GSV）功能不全的栓塞剂，关于该方法使用的结果已开始发表。据我们所知，文献中的出版物未提及静脉内CA（EVCA）栓塞的显著负面影响。我们旨在利用患者的随访数据评估这种相对较新的治疗方法的效果和不良事件，并与文献进行比较。
纳入因GSV功能不全至少3个月且接受EVCA栓塞治疗的患者。如果患者有深静脉血栓形成（DVT）、GSV过度迂曲和周围神经病变，则将其排除。查阅医院档案记录，并记录DVT、血栓性静脉炎和与该治疗程序相关的疼痛等不良事件。
为治疗GSV功能不全，共对54例平均年龄为49.36±13.06岁的患者进行了EVCA栓塞手术。在首次对照检查中，观察到1例患者从隐股交界处（SFJ）到股总静脉出现约5 mm的正丁基CA（NBCA）延伸，6个肢体出现疼痛性血栓性静脉炎反应。
我们认为，虽然EVCA栓塞是一种成功率与静脉内热消融（EVTA）相似的治疗选择，但应牢记可能会发生血栓性静脉炎以及NBCA延伸或血栓延伸至深静脉的情况。
